TCRT stock icon

Alaunos Therapeutics
TCRT

$0.62
0.83%

Market Cap: 9.93M

 

About: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Employees: 34

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

17,600% more call options, than puts

Call options by funds: $177K | Put options by funds: $1K

44% more capital invested

Capital invested by funds: $2.95M [Q4 2023] → $4.23M (+$1.29M) [Q1 2024]

2.44% less ownership

Funds ownership: 17.08% [Q4 2023] → 14.64% (-2.44%) [Q1 2024]

48% less funds holding

Funds holding: 85 [Q4 2023] → 44 (-41) [Q1 2024]

84% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 49

97% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 35

Research analyst outlook

We haven’t received any recent analyst ratings for TCRT.

Financial journalist opinion